Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPDAPT-2: Short vs conventional dual antiplatelet therapy after DES PCI
jRCTs052180194Completed
- Sponsor
- Abbott Laboratories
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised trial of clopidogrel in coronary arteriosclerosis, stable angina and myocardial infarction (MI) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Primary composite endpoint at 12 months and Primary composite endpoint at 60 months. Started Dec 2015; status: completed.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosisstable anginamyocardial infarction (MI)
Beyond the preview
Go deeper on jRCTs052180194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs052180194.